AAPL349.45-3.00 (-0.85%) ▼|ABBV280.38-5.64 (-1.97%) ▼|ABT104.48-0.23 (-0.22%) ▼|ACN227.49-11.79 (-4.93%) ▼|ADBE226.20-9.35 (-3.97%) ▼|AMAT352.30+3.07 (+0.88%) ▲|AMD530.14+26.73 (+5.31%) ▲|AMGN443.89-14.04 (-3.07%) ▼|AMT184.82+1.64 (+0.90%) ▲|AMZN267.74+9.85 (+3.82%) ▲|AVGO354.05+12.45 (+3.64%) ▲|AXP315.40-0.38 (-0.12%) ▼|BA162.91-1.00 (-0.61%) ▼|BAC48.91-0.53 (-1.07%) ▼|BKNG153.28-1.18 (-0.76%) ▼|BLK1,169.21-11.46 (-0.97%) ▼|BMY59.56-1.79 (-2.92%) ▼|BNY147.80-1.99 (-1.33%) ▼|BRK-B574.62-12.14 (-2.07%) ▼|C117.34-2.60 (-2.17%) ▼|CAT558.77-12.02 (-2.11%) ▼|CL98.85-0.76 (-0.76%) ▼|CMCSA25.24-0.07 (-0.28%) ▼|COF184.30-2.48 (-1.33%) ▼|COP134.40-5.08 (-3.64%) ▼|COST1,096.62-13.46 (-1.21%) ▼|CRM190.40-4.12 (-2.12%) ▼|CSCO97.18+2.07 (+2.18%) ▲|CVS81.35-4.46 (-5.20%) ▼|CVX205.88-8.47 (-3.95%) ▼|DE644.75-4.48 (-0.69%) ▼|DHR228.58+2.81 (+1.24%) ▲|DIS122.36+5.42 (+4.63%) ▲|DUK130.05+0.21 (+0.16%) ▲|EMR162.00+2.85 (+1.79%) ▲|FDX318.31-1.63 (-0.51%) ▼|GD349.04-6.59 (-1.85%) ▼|GE328.10+1.70 (+0.52%) ▲|GEV772.22-7.69 (-0.99%) ▼|GILD168.98-1.28 (-0.75%) ▼|GM82.13-1.92 (-2.28%) ▼|GOOG279.20+1.60 (+0.58%) ▲|GOOGL282.44+2.24 (+0.80%) ▲|GS873.18-4.34 (-0.49%) ▼|HD337.64-1.37 (-0.40%) ▼|HON222.70+3.74 (+1.71%) ▲|IBM228.53-2.56 (-1.11%) ▼|INTC54.67-0.50 (-0.91%) ▼|INTU313.24-7.55 (-2.35%) ▼|ISRG420.95-9.58 (-2.23%) ▼|JNJ272.70-6.00 (-2.15%) ▼|JPM324.11-5.85 (-1.77%) ▼|KO98.09-0.70 (-0.71%) ▼|LIN512.16-2.95 (-0.57%) ▼|LLY1,382.75-32.80 (-2.32%) ▼|LMT578.19-12.15 (-2.06%) ▼|LOW222.78+2.32 (+1.05%) ▲|LRCX211.67+0.98 (+0.47%) ▲|MA643.37-2.36 (-0.37%) ▼|MCD274.03-1.79 (-0.65%) ▼|MDLZ66.57-0.19 (-0.28%) ▼|MDT100.72-1.60 (-1.56%) ▼|META616.38-2.49 (-0.40%) ▼|MMM181.05+0.17 (+0.09%) ▲|MO76.26-1.20 (-1.55%) ▼|MRK137.78-5.59 (-3.90%) ▼|MS181.17-2.36 (-1.29%) ▼|MSFT508.29+2.05 (+0.40%) ▲|MU705.27-7.15 (-1.00%) ▼|NEE84.78+0.36 (+0.43%) ▲|NFLX59.82+0.14 (+0.23%) ▲|NKE36.31+0.46 (+1.28%) ▲|NOW90.59-2.31 (-2.49%) ▼|NVDA150.96-4.50 (-2.89%) ▼|ORCL113.89-1.11 (-0.97%) ▼|PEP141.87-0.15 (-0.11%) ▼|PFE28.06-0.41 (-1.44%) ▼|PG170.29-1.43 (-0.83%) ▼|PLTR156.67+0.11 (+0.07%) ▲|PM192.73-1.65 (-0.85%) ▼|QCOM159.81-6.86 (-4.12%) ▼|RTX197.45-0.55 (-0.28%) ▼|SBUX107.78-1.33 (-1.22%) ▼|SCHW93.65+1.09 (+1.17%) ▲|SO93.70-0.70 (-0.74%) ▼|SPG230.42-1.00 (-0.43%) ▼|T21.90-0.04 (-0.20%) ▼|TMO692.74+5.95 (+0.87%) ▲|TMUS164.02-3.88 (-2.31%) ▼|TSLA383.72+3.61 (+0.95%) ▲|TXN299.38+6.95 (+2.38%) ▲|UBER69.06+0.29 (+0.42%) ▲|UNH349.86-0.04 (-0.01%) ▼|UNP297.37-3.56 (-1.18%) ▼|UPS110.29-0.74 (-0.66%) ▼|USB58.38+0.11 (+0.19%) ▲|V411.95-3.15 (-0.76%) ▼|VZ45.81-0.32 (-0.68%) ▼|WFC81.50+0.57 (+0.71%) ▲|WMT124.52-2.84 (-2.23%) ▼|XOM161.42+0.87 (+0.54%) ▲|AAPL349.45-3.00 (-0.85%) ▼|ABBV280.38-5.64 (-1.97%) ▼|ABT104.48-0.23 (-0.22%) ▼|ACN227.49-11.79 (-4.93%) ▼|ADBE226.20-9.35 (-3.97%) ▼|AMAT352.30+3.07 (+0.88%) ▲|AMD530.14+26.73 (+5.31%) ▲|AMGN443.89-14.04 (-3.07%) ▼|AMT184.82+1.64 (+0.90%) ▲|AMZN267.74+9.85 (+3.82%) ▲|AVGO354.05+12.45 (+3.64%) ▲|AXP315.40-0.38 (-0.12%) ▼|BA162.91-1.00 (-0.61%) ▼|BAC48.91-0.53 (-1.07%) ▼|BKNG153.28-1.18 (-0.76%) ▼|BLK1,169.21-11.46 (-0.97%) ▼|BMY59.56-1.79 (-2.92%) ▼|BNY147.80-1.99 (-1.33%) ▼|BRK-B574.62-12.14 (-2.07%) ▼|C117.34-2.60 (-2.17%) ▼|CAT558.77-12.02 (-2.11%) ▼|CL98.85-0.76 (-0.76%) ▼|CMCSA25.24-0.07 (-0.28%) ▼|COF184.30-2.48 (-1.33%) ▼|COP134.40-5.08 (-3.64%) ▼|COST1,096.62-13.46 (-1.21%) ▼|CRM190.40-4.12 (-2.12%) ▼|CSCO97.18+2.07 (+2.18%) ▲|CVS81.35-4.46 (-5.20%) ▼|CVX205.88-8.47 (-3.95%) ▼|DE644.75-4.48 (-0.69%) ▼|DHR228.58+2.81 (+1.24%) ▲|DIS122.36+5.42 (+4.63%) ▲|DUK130.05+0.21 (+0.16%) ▲|EMR162.00+2.85 (+1.79%) ▲|FDX318.31-1.63 (-0.51%) ▼|GD349.04-6.59 (-1.85%) ▼|GE328.10+1.70 (+0.52%) ▲|GEV772.22-7.69 (-0.99%) ▼|GILD168.98-1.28 (-0.75%) ▼|GM82.13-1.92 (-2.28%) ▼|GOOG279.20+1.60 (+0.58%) ▲|GOOGL282.44+2.24 (+0.80%) ▲|GS873.18-4.34 (-0.49%) ▼|HD337.64-1.37 (-0.40%) ▼|HON222.70+3.74 (+1.71%) ▲|IBM228.53-2.56 (-1.11%) ▼|INTC54.67-0.50 (-0.91%) ▼|INTU313.24-7.55 (-2.35%) ▼|ISRG420.95-9.58 (-2.23%) ▼|JNJ272.70-6.00 (-2.15%) ▼|JPM324.11-5.85 (-1.77%) ▼|KO98.09-0.70 (-0.71%) ▼|LIN512.16-2.95 (-0.57%) ▼|LLY1,382.75-32.80 (-2.32%) ▼|LMT578.19-12.15 (-2.06%) ▼|LOW222.78+2.32 (+1.05%) ▲|LRCX211.67+0.98 (+0.47%) ▲|MA643.37-2.36 (-0.37%) ▼|MCD274.03-1.79 (-0.65%) ▼|MDLZ66.57-0.19 (-0.28%) ▼|MDT100.72-1.60 (-1.56%) ▼|META616.38-2.49 (-0.40%) ▼|MMM181.05+0.17 (+0.09%) ▲|MO76.26-1.20 (-1.55%) ▼|MRK137.78-5.59 (-3.90%) ▼|MS181.17-2.36 (-1.29%) ▼|MSFT508.29+2.05 (+0.40%) ▲|MU705.27-7.15 (-1.00%) ▼|NEE84.78+0.36 (+0.43%) ▲|NFLX59.82+0.14 (+0.23%) ▲|NKE36.31+0.46 (+1.28%) ▲|NOW90.59-2.31 (-2.49%) ▼|NVDA150.96-4.50 (-2.89%) ▼|ORCL113.89-1.11 (-0.97%) ▼|PEP141.87-0.15 (-0.11%) ▼|PFE28.06-0.41 (-1.44%) ▼|PG170.29-1.43 (-0.83%) ▼|PLTR156.67+0.11 (+0.07%) ▲|PM192.73-1.65 (-0.85%) ▼|QCOM159.81-6.86 (-4.12%) ▼|RTX197.45-0.55 (-0.28%) ▼|SBUX107.78-1.33 (-1.22%) ▼|SCHW93.65+1.09 (+1.17%) ▲|SO93.70-0.70 (-0.74%) ▼|SPG230.42-1.00 (-0.43%) ▼|T21.90-0.04 (-0.20%) ▼|TMO692.74+5.95 (+0.87%) ▲|TMUS164.02-3.88 (-2.31%) ▼|TSLA383.72+3.61 (+0.95%) ▲|TXN299.38+6.95 (+2.38%) ▲|UBER69.06+0.29 (+0.42%) ▲|UNH349.86-0.04 (-0.01%) ▼|UNP297.37-3.56 (-1.18%) ▼|UPS110.29-0.74 (-0.66%) ▼|USB58.38+0.11 (+0.19%) ▲|V411.95-3.15 (-0.76%) ▼|VZ45.81-0.32 (-0.68%) ▼|WFC81.50+0.57 (+0.71%) ▲|WMT124.52-2.84 (-2.23%) ▼|XOM161.42+0.87 (+0.54%) ▲|
14.6 C
New York
Thursday, November 19, 2026
Press ReleasesEnergyLupus Foundation of America-Supported Phase II Trial Shows Promise for Mesenchymal Stromal Cells as a Potential New Lupus Therapy

Lupus Foundation of America-Supported Phase II Trial Shows Promise for Mesenchymal Stromal Cells as a Potential New Lupus Therapy

Results presented at American College of Rheumatology (ACR) Convergence shows positive data with a higher dose of mesenchymal stromal cells for refractory lupus

WASHINGTON, Nov. 19, 2026 /PRNewswire/ — New data from the Lupus Foundation of America (LFA)–funded Phase II Mesenchymal Stromal Cells in Systemic Lupus Erythematosus (MiSLE) trial, evaluating a single infusion of umbilical cord-derived mesenchymal stromal cells (MSCs) in adults with active systemic lupus erythematosus (SLE) that had not responded adequately to standard treatment, marks a promising step forward in the search for new treatment options.

Lupus Foundation of America. (PRNewsFoto/Lupus Foundation of America)

The study, authored by Gary S. Gilkeson, MD, Distinguished University Professor of Medicine, Microbiology, and Immunology at Medical University of South Carolina (MUSC), and co-author/presented by Diane L. Kamen, MD, MSCR, a professor at MUSC, Division of Rheumatology and Immunology, was shared on November 10 in a late-breaking presentation at this year’s American College of Rheumatology (ACR) annual meeting. While the trial did not meet its primary efficacy endpoint at 24 weeks with the high dose/low dose groups combined vs placebo, secondary analyses identified significant disease improvement with the higher dose of MSCs with very reassuring safety. These findings warrant a confirmatory trial which is in development.

“The improvements in lupus activity we observed, especially among patients who received the higher dose, are promising and give us a clearer direction for future research,” said Dr. Kamen. “We now intend to test these findings in a confirmatory trial of the higher 5 × 10⁶ cells/kg dose, including evaluation of repeat dosing to determine whether the early responses can be sustained over time.”

Findings to guide the next stage of research

The primary endpoint was response at Week 24 on a modified SLE Responder Index-4 (SRI-4), which combines measures of disease activity with limits on steroid and other immunosuppressant use. Eighty-one patients were enrolled at nine US Lupus Centers with 27 patients receiving low dose MSCs (one million/kg), 27 receiving high dose MSCs (five million/kg) and 27 receiving placebo. The response measure combined improvement in lupus disease activity with limits on worsening disease and medication use, including a prednisone dose of no more than 10 mg daily beginning at Week 20. At week 24, 38.9% of MSC-treated participants met the modified SRI-4 response criteria, compared with 23.1% receiving placebo a difference of 15.8 percentage points that favored the MSC group but did not reach statistical significance (adjusted p = 0.156).

Secondary analyses provided additional findings to guide future research:

Higher-dose response at Week 24: Response rate was 48.1% with 5 million cells/kg versus 29.6% in the lower-dose group and 23.1% in the pooled placebo group. This comparison revealed a 25% difference in response between high dose group and placebo and approached statistical significance (adjusted p = 0.054).

Earlier response signals: Secondary analyses using the unmodified SRI-4 showed significant benefits between the higher dose and its within-cohort placebo group at Weeks 12, 16 and 20. (p =0.03-0.04 at each time point).

Per-protocol response: Using analysis by per-protocol response, which excludes patients with major protocol deviations prior to week 24 (for example, having received high-dose steroids for non-lupus indications) the week 24 response was 68.4% (13 of 19) with the higher dose versus 30.0% (6 of 20) in the pooled placebo group (adjusted p = 0.0087).

Disease activity over time: Scores on the SLE Disease Activity Index (SLEDAI), a measure of lupus disease activity, fell in all three groups. At Week 12, median scores declined by four points in both MSC groups versus two points with placebo. At week 24, the median score of the high dose group was decreased more than the other two groups. After week 24, patients in any of the groups could be treated with any immunosuppressant, biologic or prednisone dose. By Week 52, the low-dose MSC group had the largest median decrease (six points). Differences in baseline disease activity limit direct comparisons between groups.

Safety findings: Safety was assessed through Week 52. Serious adverse events (SAE) occurred in 27.8% of participants receiving MSCs (44.4% of the low dose cohort and 11.1% of the higher-dose cohort) and 14.8% receiving placebo overall. None of the SAEs were attributed to the study drug. . Serious infections occurred in 7.4% of MSC-treated participants and 3.7% of placebo recipients overall with the high dose MSC group having fewer infections. One death occurred by suicide in the placebo group early in the study. No deaths occurred among the 54 MSC recipients.

About the MiSLE lupus cell therapy trial

The MiSLE study is the first multicenter, randomized, double-blind, placebo-controlled trial of allogeneic umbilical cord–derived MSCs in adults with active SLE. These cells come from donor umbilical cord tissue and are being studied for their ability to regulate immune activity. Lupus is a chronic autoimmune disease in which the immune system attacks the body’s own tissues and organs.

Conducted across nine clinical centers, MiSLE evaluated intravenous infusions of either 1 million or 5 million cells per kilogram of body weight, added to standard care. Participants were randomized to MSCs or placebo within two sequential dose cohorts. Of 87 randomized participants, 81 received an infusion: 54 received MSCs and 27 received placebo. The primary efficacy analysis included 80 participants after one placebo participant withdrew consent. Participants had been living with lupus for a median of 12.9 years at enrollment and among the 81 who received an infusion, approximately 89% were female and 36% were Black.

Building on years of research and community support

The Lupus Foundation of America has supported MSC research since 2012, including a $3.8 million commitment announced in 2018 for the Phase 2 trial. MiSLE was supported by Lupus Foundation of America and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The Lupus Foundation of America also supported community awareness and participant recruitment.

“People living with lupus deserve more than treatments that simply manage their symptoms. They deserve new options that offer hope for better disease control, improved quality of life and a future where lupus no longer dictates how they live,” said Louise Vetter, President and CEO of the Lupus Foundation of America. “MiSLE reflects years of support in an approach with the potential to address this unmet need. We are extremely encouraged by these findings and deeply grateful to the participants, families and research teams who are helping drive the needle forward towards a cure.”

The study team also acknowledged the investigators and coordinators at all nine clinical sites, the MUSC Data Coordination Unit and Clean Cell Facility, the NIAID research team, and the Data and Safety Monitoring Board.

To learn more about LFA’s longstanding support, funding and involvement with stromal cell research, visit: https://www.lupus.org/our-work/stromal-cell-research

About the Lupus Foundation of America 

The Lupus Foundation of America is the premier patient advocacy organization devoted to solving the mystery of lupus, a devastating autoimmune condition where the immune system attacks organs throughout the body, while giving caring support to those who suffer from its brutal impact. Through a comprehensive program of research, education, and advocacy, we lead the fight to improve the quality of life for all people affected by lupus. Learn more about the Lupus Foundation of America at lupus.org. 

Contact:

Mike Donnelly

donnelly@lupus.org

(202) 349-1162

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lupus-foundation-of-america-supported-phase-ii-trial-shows-promise-for-mesenchymal-stromal-cells-as-a-potential-new-lupus-therapy-302945061.html

SOURCE Lupus Foundation of America, Inc.

Recent News